

# Michal Sarfaty

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6990489/publications.pdf>

Version: 2024-02-01

32  
papers

499  
citations

858243

12  
h-index

759306

22  
g-index

33  
all docs

33  
docs citations

33  
times ranked

845  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 875.	1.7	3
2	Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4522-4522.	0.8	3
3	RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. <i>Cancers</i> , 2022, 14, 3127.	1.7	5
4	Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 423-432.	1.1	5
5	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 379-387.	1.1	3
6	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	0.9	2
7	Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. <i>Breast</i> , 2021, 60, 62-69.	0.9	88
8	A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	1.3	10
9	The Cost of Enfortumab Vedotin Wastage Due to Vial Size – A Real-World Analysis. <i>Cancers</i> , 2021, 13, 5977.	1.7	1
10	Next-generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage – Multicenter experience. <i>Head and Neck</i> , 2020, 42, 599-607.	0.9	8
11	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. <i>Cancer Medicine</i> , 2020, 9, 4603-4612.	1.3	3
12	Antibody-Drug Conjugates in Urothelial Carcinomas. <i>Current Oncology Reports</i> , 2020, 22, 13.	1.8	21
13	MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17034-e17034.	0.8	0
14	Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz033.	1.4	20
15	The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States. <i>Clinical Colorectal Cancer</i> , 2019, 18, 209-217.	1.0	6
16	A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate-to Poor-Risk Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 366-371.	1.9	26
17	The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	22
18	Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. <i>European Urology</i> , 2018, 74, 57-62.	0.9	56

#	ARTICLE	IF	CITATIONS
19	Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2018, 73, 628-634.	0.9	57
20	Early PET-CT in patients with pathological stage III colon cancer may improve their outcome: Results from a large retrospective study. <i>Cancer Medicine</i> , 2018, 7, 5470-5477.	1.3	3
21	RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients. <i>Clinical Lung Cancer</i> , 2017, 18, e223-e232.	1.1	24
22	Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab. <i>Medicine (United States)</i> , 2017, 96, e5951.	0.4	15
23	Esophageal Cancer in Israel has Unique Clinico-Pathological Features: A Retrospective Study. <i>Journal of Cancer</i> , 2017, 8, 2417-2423.	1.2	3
24	Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. <i>Radiation Oncology</i> , 2017, 12, 163.	1.2	55
25	Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. <i>Journal of Cancer</i> , 2016, 7, 883-889.	1.2	4
26	Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World. <i>Oncologist</i> , 2016, 21, 907-909.	1.9	13
27	A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. <i>PLoS ONE</i> , 2016, 11, e0157548.	1.1	5
28	Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profilng-Guided Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	11
29	Esophageal cancer in Israel: A unique clinicopathological entity?. <i>Journal of Clinical Oncology</i> , 2015, 33, e15050-e15050.	0.8	0
30	Are all RET fusions NSCLC alike? Clinical pitfalls and response to targeted therapy: KIF5B vs. CCDC6.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19005-e19005.	0.8	0
31	New paradigm for the treatment of metastatic salivary gland tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17043-e17043.	0.8	0
32	Outcome of percutaneous endoscopic gastrostomy insertion in patients with amyotrophic lateral sclerosis in relation to respiratory dysfunction. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 528-532.	1.1	27